Literature DB >> 18559974

Crystal structures of TAFI elucidate the inactivation mechanism of activated TAFI: a novel mechanism for enzyme autoregulation.

Pauline F Marx1, T Harma C Brondijk, Tom Plug, Roland A Romijn, Wieger Hemrika, Joost C M Meijers, Eric G Huizinga.   

Abstract

Thrombin-activatable fibrinolysis inhibitor (TAFI) is a pro-metallocarboxypeptidase that can be proteolytically activated (TAFIa). TAFIa is unique among carboxypeptidases in that it spontaneously inactivates with a short half-life, a property that is crucial for its role in controlling blood clot lysis. We studied the intrinsic instability of TAFIa by solving crystal structures of TAFI, a TAFI inhibitor (GEMSA) complex and a quadruple TAFI mutant (70-fold more stable active enzyme). The crystal structures show that TAFIa stability is directly related to the dynamics of a 55-residue segment (residues 296-350) that includes residues of the active site wall. Dynamics of this flap are markedly reduced by the inhibitor GEMSA, a known stabilizer of TAFIa, and stabilizing mutations. Our data provide the structural basis for a model of TAFI auto-regulation: in zymogen TAFI the dynamic flap is stabilized by interactions with the activation peptide. Release of the activation peptide increases dynamic flap mobility and in time this leads to conformational changes that disrupt the catalytic site and expose a cryptic thrombin-cleavage site present at Arg302. This represents a novel mechanism of enzyme control that enables TAFI to regulate its activity in plasma in the absence of specific inhibitors.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18559974     DOI: 10.1182/blood-2008-03-146001

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  17 in total

1.  Plasma carboxypeptidase B downregulates inflammatory responses in autoimmune arthritis.

Authors:  Jason J Song; Inyong Hwang; Kyung H Cho; Michael A Garcia; Arthur J Kim; Tiffany H Wang; Tamsin M Lindstrom; Annette T Lee; Toshihiko Nishimura; Lei Zhao; John Morser; Michael Nesheim; Stuart B Goodman; David M Lee; S Louis Bridges; Peter K Gregersen; Lawrence L Leung; William H Robinson
Journal:  J Clin Invest       Date:  2011-08-01       Impact factor: 14.808

2.  Microneme protein 5 regulates the activity of Toxoplasma subtilisin 1 by mimicking a subtilisin prodomain.

Authors:  Savvas Saouros; Zhicheng Dou; Maud Henry; Jan Marchant; Vern B Carruthers; Stephen Matthews
Journal:  J Biol Chem       Date:  2012-08-15       Impact factor: 5.157

3.  Flexibility of the thrombin-activatable fibrinolysis inhibitor pro-domain enables productive binding of protein substrates.

Authors:  Zuzana Valnickova; Laura Sanglas; Joan L Arolas; Steen V Petersen; Christine Schar; Daniel Otzen; Francesc X Aviles; F Xavier Gomis-Rüth; Jan J Enghild
Journal:  J Biol Chem       Date:  2010-09-29       Impact factor: 5.157

4.  Substrate specificity of human carboxypeptidase A6.

Authors:  Peter J Lyons; Lloyd D Fricker
Journal:  J Biol Chem       Date:  2010-09-20       Impact factor: 5.157

5.  Kinetics of activated thrombin-activatable fibrinolysis inhibitor (TAFIa)-catalyzed cleavage of C-terminal lysine residues of fibrin degradation products and removal of plasminogen-binding sites.

Authors:  Jonathan H Foley; Paul F Cook; Michael E Nesheim
Journal:  J Biol Chem       Date:  2011-04-05       Impact factor: 5.157

6.  The roles of selected arginine and lysine residues of TAFI (Pro-CPU) in its activation to TAFIa by the thrombin-thrombomodulin complex.

Authors:  Chengliang Wu; Paul Y Kim; Reg Manuel; Marian Seto; Marc Whitlow; Mariko Nagashima; John Morser; Ann Gils; Paul Declerck; Michael E Nesheim
Journal:  J Biol Chem       Date:  2008-12-12       Impact factor: 5.157

Review 7.  Carboxypeptidase U (TAFIa): a new drug target for fibrinolytic therapy?

Authors:  J L Willemse; E Heylen; M E Nesheim; D F Hendriks
Journal:  J Thromb Haemost       Date:  2009-08-28       Impact factor: 5.824

8.  Low thrombin activatable fibrinolysis inhibitor activity levels are associated with an increased risk of a first myocardial infarction in men.

Authors:  Mirjam E Meltzer; Carine J M Doggen; Philip G de Groot; Joost C M Meijers; Frits R Rosendaal; Ton Lisman
Journal:  Haematologica       Date:  2009-04-18       Impact factor: 9.941

9.  An Analysis of MIF Structural Features that Control Functional Activation of CD74.

Authors:  Georgios Pantouris; Mansoor Ali Syed; Chengpeng Fan; Deepa Rajasekaran; Thomas Yoonsang Cho; Eric M Rosenberg; Richard Bucala; Vineet Bhandari; Elias J Lolis
Journal:  Chem Biol       Date:  2015-09-10

10.  Biochemical characterization of bovine plasma thrombin-activatable fibrinolysis inhibitor (TAFI).

Authors:  Zuzana Valnickova; Morten Thaysen-Andersen; Peter Højrup; Trine Christensen; Kristian W Sanggaard; Torsten Kristensen; Jan J Enghild
Journal:  BMC Biochem       Date:  2009-05-05       Impact factor: 4.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.